Efficacy and safety of 5% minoxidil topical foam in male pattern hair loss treatment and patient satisfaction.
Male pattern hair loss is widespread around the world. Its prevalence indicates the importance of finding the best treatment modalities. This study evaluates the efficacy and safety of minoxidil 5% topical foam in male pattern hair loss treatment and patient satisfaction.



This study was a before-and-after trial on 17 male patients with male pattern hair loss. Subjects were instructed to apply one capful (1 ml) of minoxidil 5% topical foam on the scalp daily for 6 months. Efficacy was assessed through hair counts, subject assessment, and global photographic review.



Seventeen male volunteers were recruited, and three volunteers were withdrawn; 14 participated in the trial for 16 weeks, and 12 continued up to 24 weeks. The average hair count with a camera at week 16 (181.87 ± 52.42) and week 24 (194.58 ± 62.82) and with an eye count at week 16 (62.57 ± 15.28) and week 24 (69.91 ± 15.61) increased significantly compared to the baseline after intervention.



This study confirmed that minoxidil 5% topical foam is a safe and effective treatment for MPHL. The effect of it is evident after 24 weeks of use.
Pharmaceutical, Cosmeceutical, and Hygienic Skin Products Clinical Evaluation Lab (DermaLab), Center for Research & Training in Skin Diseases & Leprosy (CRTSDL), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Hournaz
H
Hasanzadeh
Pharmaceutical, Cosmeceutical, and Hygienic Skin Products Clinical Evaluation Lab (DermaLab), Center for Research & Training in Skin Diseases & Leprosy (CRTSDL), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Saman Ahmad
SA
Nasrollahi
Clinical Trial Center (CTC), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Nader
N
Halavati
Community-Based Participatory Research Center, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sci­ences (TUMS), Tehran, Iran.
Maryam
M
Saberi
Pharmaceutical, Cosmeceutical, and Hygienic Skin Products Clinical Evaluation Lab (DermaLab), Center for Research & Training in Skin Diseases & Leprosy (CRTSDL), Tehran University of Medical Sciences (TUMS), Tehran, Iran.|Clinical Trial Center (CTC), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Alireza
A
Firooz
D000287:Administration, Topical; D000328:Adult; D000505:Alopecia / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008914:Minoxidil / Q000627:therapeutic use*; D017060:Patient Satisfaction; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*; D055815:Young Adult
D014665:Vasodilator Agents; D008914:Minoxidil